NCT03425552View on ClinicalTrials.gov

A Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 mg in the Form of a Prolonged Release Suspension for Injection in Patients With Schizophrenia Who Are Already Stabilized in This Treatment

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

March 11, 2018

Primary Completion Date

May 2, 2019

Study Completion Date

May 2, 2019

Conditions
Schizophrenia
Interventions
DRUG

Paliperidone

Paliperidone Palmitate extended-release injectable suspension 156 mg (100 mg of Paliperidone)

DRUG

Paliperidone

Paliperidone Palmitate 156 mg (equivalent to Paliperiodne 100 mg) extended release injectable suspension

Trial Locations (3)

Unknown

Al-Esraa Hospital, Amman

King Abdullah University Hospital, Ar Ramtha

Princes Basma Teaching Hospital, Irbid

Sponsors

Lead Sponsor

Pharmathen S.A.
All Listed Sponsors
lead

Pharmathen S.A.

INDUSTRY

NCT03425552 - A Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 mg in the Form of a Prolonged Release Suspension for Injection in Patients With Schizophrenia Who Are Already Stabilized in This Treatment | Biotech Hunter | Biotech Hunter